ArticleHeart and vessels2016
Correlation of NLRP3 with severity and prognosis of coronary atherosclerosis in acute coronary syndrome patients.
Article in Heart and vessels, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04191642 (Correlation of NLRP3 With Cognitive Dysfunction Early After Heart Valve), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation of NLRP3 With Cognitive Dysfunction Early After Heart Valve
Who cites it
45 citing papers in PubMed, 93 citations in OpenAlex.
- Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.Nature reviews. Cardiology · 2026Review
- The diagnostic and prognostic value of sTM, t-PAIC, and NLRP3 in ICU patients with sepsis.BMC infectious diseases · 2026Article
- Predictive Value of NLRP3 Inflammasome Activation for Unstable Plaques and Major Adverse Cardiovascular Events in Coronary Heart Disease.Journal of inflammation research · 2026Article
- Inflammasomes in Cardiovascular Diseases: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2025Review
- Therapeutic Targeting of Pattern Recognition Receptors to Modulate Inflammation in Atherosclerosis.Cell biochemistry and biophysics · 2025Review
- The effect of NLRP3 inflammasome on cardiovascular prognosis in patients with acute coronary syndrome.Scientific reports · 2025Article
- The Expression Characteristics and Interrelationships of FNDC5 and Pyroptosis-Associated Molecules in the Peripheral Blood of Patients with Coronary Heart Disease.Current protein & peptide science · 2025Article
- The Role of Bacterial Extracellular Membrane Nanovesicles in Atherosclerosis: Unraveling a Potential Trigger.Current atherosclerosis reports · 2024Review
- Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.Scientific reports · 2024Observational
- Investigating the expression level of miR-17-3p, miR-101-3p, miR-335-3p, and miR-296-3p in the peripheral blood of patients with acute myocardial infarction.Molecular and cellular biochemistry · 2024Article
- The Role of Epicardial Adipose Tissue in Acute Coronary Syndromes, Post-Infarct Remodeling and Cardiac Regeneration.International journal of molecular sciences · 2024Review
- Colchicine ameliorates myocardial injury induced by coronary microembolization through suppressing pyroptosis via the AMPK/SIRT1/NLRP3 signaling pathway.BMC cardiovascular disorders · 2024Article
- Association between NLRP3 inflammasome and periprocedural myocardial injury following elective PCI.Heliyon · 2023Article
- Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets.International journal of molecular sciences · 2023Review
- The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives.International journal of molecular sciences · 2023Review
- Bibliometric evaluation of publications on inflammasomes in atherosclerosis from 2002 to 2022.Frontiers in cardiovascular medicine · 2023Article
- Anti-malarial artesunate ameliorates atherosclerosis by modulating arterial inflammatory responsesFrontiers in pharmacology · 2023Article
- Negative Correlation between Serum NLRP3 and the Ratio of Treg/Th17 in Patients with Obstructive Coronary Artery Disease.Reviews in cardiovascular medicine · 2022Article
- Pyroptosis in NLRP3 inflammasome-related atherosclerosis.Cell stress · 2022Review
- Age and Chronodisruption in Mouse Heart: Effect of the NLRP3 Inflammasome and Melatonin Therapy.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We decided to assess the prognostic value of NLRP3 inflammasome level in acute coronary syndrome (ACS) patients and whether it was related to coronary atherosclerotic severity. Study population included one-hundred and twenty-three (123) subjects. Peripheral blood monocyte NLRP3 protein level was correlated with clinical presentation, angiographic characteristics and its scoring systems as well as GRACE and TIMI risk scores. Follow-up for major adverse cardiac events (MACE) was carried out at 180 days. Peripheral blood monocyte NLRP3 was found to be elevated in ACS patients (P < 0.05) and showed positive correlation with GRACE score (r = 0.619), TIMI score (r = 0.580), SYNTAX score (r = 0.550), Clinical SYNTAX score (r = 0.564) and Gensini score (r = 0.516). NLRP3 was also increased with increasing number of vessels, the number of lesions present and the presence bifurcation lesions (P < 0.05). Multivariate Cox regression analysis showed NLRP3 to be an independent predictor of MACE (P = 0.043). Kaplan-Meier analysis and receiver operating characteristic curves for NLRP3 showed good predictive value for MACE. There is a positive correlation of NLRP3 level with severity of coronary atherosclerosis. NLRP3 level is a promising prognostic utility and is efficient in event prediction for MACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.